Japan introduced a new health coverage scheme for long-listed products (LLPs) on October 1. A survey of generic drug makers…
BUSINESS
Novartis Rolls Out Luxturna in Japan, 2 Treatment Facilities Selected
Novartis Pharma on August 30 launched its gene therapy Luxturna (voretigene neparvovec) for inherited retinal disease in Japan. The treatment will be available at two facilities designated by an academic society. The product is indicated for the treatment of inherited…
To read the full story
Related Article
- Japan Society to Select Facilities to Use Luxturna; 10 Sites for Genetic Testing, 2 or 3 for Treatment
August 25, 2023
- Ultra-High Cost of Luxturna Would Be Offset by Its Clinical Significance, Have Limited Financial Impact: Expert
August 25, 2023
- Luxturna Priced at 49.6 Million Yen per Vial, Peak Sales Put at 500 Million Yen with 5 Patients
August 24, 2023
- Drug Pricing Rules to Be Applied to Novartis’ Gene Therapy Luxturna
July 6, 2023
- Japan Approves Novartis’ Gene Therapy Luxturna for Rare Eye Disease
June 27, 2023
- Japan Approves 1st Gene Panel Testing for IRD
June 6, 2023
- Gene Therapy Luxturna Now in Line for Approval in June
May 29, 2023
BUSINESS
- Asahi Kasei Offshoot to Develop Cancer Vaccine Using Proprietary DDS Base
October 11, 2024
- Ono Snags Worldwide Rights to LigaChem’s ADC Assets
October 11, 2024
- Incubation JV of Takeda, Astellas, SMBC Boots Up in Japan
October 11, 2024
- Opdivo Approved for 1st Line Bladder Cancer Use in Taiwan: Ono
October 11, 2024
- Meiji Rebuts Nursing Group’s Claim on Concerns over Kostaive
October 10, 2024
It’s easy to spot motivated and engaged employees. They are more productive, they go the extra mile, and they display a sense of ownership in their work.But how do you replicate this culture throughout your organization? How do you encourage…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…